Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-010942
Filing Date
2025-04-17
Accepted
2025-04-17 18:11:17
Documents
2
Period of Report
2025-04-15

Document Format Files

Seq Description Document Type Size
1 form3-04172025_100414.html 3  
1 form3-04172025_100414.xml 3 1674
2 ex24-04172025_100415.htm EX-24 6217
  Complete submission text file 0001415889-25-010942.txt   9517
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Issuer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 508 WRANGLER DRIVE, SUITE 100 COPPELL TX 75019
Business Address
Smith Cynthia (Reporting) CIK: 0001609480 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36279 | Film No.: 25848715